For over 50 years, Bloomberg Tax’s renowned flagship daily news service, Daily Tax Report® has helped leading practitioners and policymakers stay on the cutting edge of taxation and...
Oct. 6 — Corporate inversions have gained popularity because of the tax savings they generate, but in order to complete the deal, some shareholders can be forced to pay taxes on only-on-paper capital gains.
A group of Medtronic Inc. shareholders is suing the company saying the medical device maker's 2014 inversion with Irish Covidien Plc caused them injury because they were forced to pay tax on gains when they exchanged their Medtronic shares for stock in the combined company ( Merenstein v. Medtronic, Inc., Minn., No. A15-0858, oral arguments 10/5/16 ).
The company's management didn't uphold its fiduciary duty to a minority of the shareholders, the plaintiff's attorneys said.
Tax attorneys representing the investors told the Minnesota Supreme Court Oct. 5 some shareholders were unequally treated because tax-exempt investors, such as pension funds, didn't have to pay tax on the transaction. Medtronic's attorneys said all stockholders faced a “taxable event” and the amount they did—or didn't—have to pay because of that isn't relevant. The share price increase—from about $64 before the merger announcement up to the nearly $86 it trades for now—shows the deal benefited all the corporation's shareholders, the Medtronic attorneys said (116 DTR G-1, 6/17/14).
Merenstein highlights the complicated accounting that companies face when structuring these deals to avoid Treasury Department penalties. Government regulations require U.S. shareholders to own less than 60 percent of the combined company, which can dilute the investors' stake. If U.S. shareholders own more than 50 percent, exchanging the old stock for the new stock can trigger capital gain.
To save tax in the long run, shareholders are hit with a capital gains tax in the short run and a lesser portion of the company.
“Nirvana is if you fall below 50 percent,” Robert Willens, a tax consultant in New York, told Bloomberg BNA Oct. 6. “If you fall below that then the shareholders are protected as well as the corporation.”
The Minnesota Supreme Court usually issues opinions within 90 days, though there is no formal deadline. A favorable outcome for the shareholders could set a precedent for future cases that pit an inverted company against its shareholders.
Lockridge Grindal Nauen PLLP represents Merenstein. Robins Kaplan LLP is representing Medtronic.
A similar lawsuit, Gumm v. Molinaroli, was filed in the U.S. District Court for the Eastern District of Wisconsin in August. Shareholders of Johnson Controls Inc. are suing the company over the capital gain they had to pay in the inversion with Tyco International Plc. That deal closed in September.
Many of the large-scale inversions attempted in recent years were structured so that shareholders of the U.S. corporation held as close as possible to 60 percent, but without going over that threshold to avoid adverse Treasury action. That threshold, however, could change as foreign companies gain size through organic growth and acquisitions, Willens said.
A foreign acquirer larger than its domestic target isn't usually inclined to give U.S. shareholders more than half of the control of the company. A recent example is Henderson Group Plc’s merger with Janus Capital Group Inc. to create a $320 billion asset manager announced Oct. 2. The Janus shareholders will hold 43 percent of the company, Willens said.
“When the foreign companies are larger and more muscular,” Willens said, “you can avoid more pitfalls.”
To contact the reporter on this story: Laura Davison in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Meg Shreve at email@example.com
A video of the Minnesota Supreme Court oral arguments is at http://www.mncourts.gov/SupremeCourt/OralArgumentWebcasts/ArgumentDetail.aspx?cn=A15-0858.
Copyright © 2016 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)